(secondQuint)Palbociclib In Progressive Brain Metastases.

 - This research study is a Phase II clinical trial.

 Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease.

 "Investigational" means that the intervention is being studied.

 - This is a study designed to evaluate the efficacy and safety of palbociclib in recurrent brain metastases.

 Palbociclib is being studied for use in the treatment of a broad range of cancers.

 This type of drug inhibits cell growth in the cells called cyclin-dependent kinases which promote tumor cell proliferation.

 - The FDA (the U.

S.

 Food and Drug Administration) has not approved palbociclib for participants specific disease but it has been approved for other uses.

 Palbociclib In Progressive Brain Metastases@highlight

This research study is studying palbociclib as a possible treatment for recurrent brain metastases.

 - Pfizer, a pharmaceutical company, is supporting this research study by providing the study drug as well as funding for research activities